Pfizer Inc. (NYSE:PFE) Shares Purchased by Summit Financial Wealth Advisors LLC

Summit Financial Wealth Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 36.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 107,012 shares of the biopharmaceutical company’s stock after purchasing an additional 28,815 shares during the period. Summit Financial Wealth Advisors LLC’s holdings in Pfizer were worth $2,804,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. PSI Advisors LLC increased its stake in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Pfizer by 1.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 391 shares during the period. D Orazio & Associates Inc. lifted its position in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 391 shares during the last quarter. Lipe & Dalton boosted its stake in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC increased its position in shares of Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 401 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 3.5 %

PFE stock traded down $0.78 during midday trading on Thursday, hitting $21.71. The stock had a trading volume of 15,517,829 shares, compared to its average volume of 39,953,468. The firm has a market cap of $123.13 billion, a PE ratio of 15.40, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company’s 50-day moving average price is $25.42 and its 200 day moving average price is $26.51.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the business earned $0.10 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group cut their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.